We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 21, 2021

IVIG Safe and Effective to Treat Moderate Pneumonia in COVID-19 Patients

The Journal of Infectious Diseases

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Infectious Diseases
A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in COVID-19 Patients With Regular Intravenous Immunoglobulin Therapy
J. Infect. Dis 2021 Feb 15;[EPub Ahead of Print], RS Raman, VB Barge, AK Darivenula, H Dandu, RR Kartha, V Bafna, VT Aravinda, TC Raghuram

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading